News Could Daiichi Sankyo have another ADC winner in cancer? New data point to impressive efficacy in advanced EGFR-mutated non-small cell lung cancer.
News Merck suffers a setback in its TIGIT programme Missed endpoint in mid-stage study in lung cancer is a worry after other TIGIT failures.
News Servier’s $1.8bn Agios deal delivers glioma prospect IDH inhibitor vorasidenib could be practice changing in this form of brain cancer, says firm.
News Exscientia builds cancer pipeline with two BMS drugs LSD1 and MALT1 inhibitors inherited from BMS alliance will be biotech's next cancer candidates.
News Mersana stung by FDA hold on STING drug Death in ph1 trial casts a pall over GSK-backed project, licensed for $100m upfront last year.
News Rumour of Pfizer, Seagen deal is true, with $43bn price tag Pfizer says Seagen's current and future drugs could add $10 billion to its revenues from 2030.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
